呼吸器感染症に対するNM441の臨床検討  [in Japanese] Clinical study on NM441 against respiratory tract infection  [in Japanese]

Access this Article

Search this Article

Author(s)

Abstract

NM441を急性あるいは慢性の呼吸器感染症15例 (急性気管支炎2例, 肺炎9例, 慢性気管支炎2例, 中葉症候群の気道感染1例, 陳旧性肺結核+感染1例) に対して1回100mgまたは200mg, 1日2回経口投与し, その臨床効果, 細菌学的効果, 副作用および臨床検査値の異常変動について検討した。臨床効果は15例中14例で判定が可能であり, 「著効」4例, 「有効」9例, 「無効」1例, 「判定不能」1例で, 有効率 (「著効」+「有効」) は92.9%(13/14) であった。<BR>細菌学的効果は4例より<I>Haemophilus influenzae</I> 3株, <I>Burkholderia cepacia </I>1株の計4株が分離され, <I>H. influenzae</I>はすべて消失したが, <I>B.cepacia</I>は菌数の減少にとどまり, 4株中3株の消失であった。<BR>副作用は悪心・嘔吐が1例にみられ, 臨床検査値異常変動はBUNの上昇・直接クームス試験の陽性化が1例に認められたが, 特に問題となるものはなかった。<BR>以上のことから, 本剤は中等症以下の急性および慢性の呼吸器感染症の治療に有用な薬剤であると思われた。

NM441 was orally administered to 15 patients with acute or chronic respiratory infections (2 cases with acute bronchitis, 9 with pneumonia, 2 with chronic bronchitis, 1 with middle lobe syndrome with infection and 1 with old pulmonary tuberculosis with infection) at a dose of 100 or 200mg twice a day, and its clinical efficacy, bacteriological efficacy, side effects and abnormal laboratory findings were investigated.<BR>The clinical efficacy was excellent in 4 cases, good in 9, poor in 1 and unknown in 1, with the efficacy rate of 92.9%.<BR>In the bacteriological efficacy, a total of 4 strains, 3 strains of <I>Haemophilus influenzae</I> and 1 of <I>Burkholderia cepacia</I> were isolated from 4 patients. All of <I>H. influenzae</I> were eradicated and <I>B. cepacia</I> was decreased.<BR>Though nausea·vomiting was observed in 1 patient as a side effect and an elevation of BUN·Coombs' test positive was observed in 1 as an abnormal laboratory finding, both of them were not particularly problematic.<BR>From the above results, NM441 was considered as a useful drug for the treatment of mild or moderate respiratory tract infections.

Journal

  • Japanese Journal of Chemotherapy

    Japanese Journal of Chemotherapy 44, 626-629, 1996-03-01

    Japanese Society of Chemotherapy

References:  4

Codes

Page Top